Why the study?
In 2020, an international panel proposed a novel comprehensive redefinition of fatty liver disease, motivating a review of its impact on understanding epidemiology, pathogenesis, diagnosis, and clinical trials.
Does the MAFLD definition improve the identification of high-risk patients compared to the NAFLD definition in patients with fatty liver disease?
Does the MAFLD definition improve the identification of high-risk patients compared to the NAFLD definition in patients with fatty liver disease?
The transition from NAFLD to MAFLD criteria improves the identification of patients at high risk for metabolic and hepatic complications.
Answers are grounded in this paper and cite their sources.
MAFLD may improve risk stratification in fatty liver; leaves open whether criteria should supplant NAFLD pending prospective validation.
PURPOSE OF REVIEW: In 2020, a novel comprehensive redefinition of fatty liver disease was proposed by an international panel of experts. This review aims to explore current evidence regarding the impact of this new definition on the current understanding of the epidemiology, pathogenesis, diagnosis, and clinical trials for fatty liver disease. RECENT FINDINGS: The effectiveness of metabolic dysfunction-associated fatty liver disease (MAFLD) was compared to the existing criteria for nonalcoholic fatty liver disease (NAFLD). Recent data robustly suggest the superior utility of MAFLD in identifying patients at high risk for metabolic dysfunction, the hepatic and extra-hepatic complications, as well as those who would benefit from genetic testing, including patients with concomitant liver diseases. This change in name and criteria also appears to have improved disease awareness among patients and physicians. SUMMARY: The transformation in name and definition from NAFLD to MAFLD represents an important milestone, which indicates significant tangible progress towards a more inclusive, equitable, and patient-centred approach to addressing the profound challenges of this disease. Growing evidence has illustrated the broader and specific contexts that have tremendous potential for positively influencing the diagnosis and treatment. In addition, the momentum accompanying this name change has included widespread public attention to the unique burden of this previously underappreciated disease.
No takes yet. Share an insight, caveat, or question.
A 2022 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: